These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8626884)
1. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. Zhi J; Melia AT; Eggers H; Joly R; Patel IH J Clin Pharmacol; 1995 Nov; 35(11):1103-8. PubMed ID: 8626884 [TBL] [Abstract][Full Text] [Related]
2. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. Zhi J; Mulligan TE; Hauptman JB J Clin Pharmacol; 1999 Jan; 39(1):41-6. PubMed ID: 9987699 [TBL] [Abstract][Full Text] [Related]
3. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Melia AT; Zhi J; Zelasko R; Hartmann D; Güzelhan C; Guerciolini R; Odink J Eur J Clin Pharmacol; 1998; 54(9-10):773-7. PubMed ID: 9923583 [TBL] [Abstract][Full Text] [Related]
4. Mode of action of orlistat. Guerciolini R Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S12-23. PubMed ID: 9225172 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat. Hussain Y; Güzelhan C; Odink J; van der Beek EJ; Hartmann D J Clin Pharmacol; 1994 Nov; 34(11):1121-5. PubMed ID: 7876405 [TBL] [Abstract][Full Text] [Related]
6. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Zhi J; Melia AT; Guerciolini R; Chung J; Kinberg J; Hauptman JB; Patel IH Clin Pharmacol Ther; 1994 Jul; 56(1):82-5. PubMed ID: 8033498 [TBL] [Abstract][Full Text] [Related]
7. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. Zhi J; Melia AT; Koss-Twardy SG; Arora S; Patel IH J Clin Pharmacol; 1996 Feb; 36(2):152-9. PubMed ID: 8852391 [TBL] [Abstract][Full Text] [Related]
8. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. Zhi J; Melia AT; Funk C; Viger-Chougnet A; Hopfgartner G; Lausecker B; Wang K; Fulton JS; Gabriel L; Mulligan TE J Clin Pharmacol; 1996 Nov; 36(11):1006-11. PubMed ID: 8973989 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic equivalence of two orlistat capsule formulations in healthy volunteers under fed conditions. Di Marco M; Marier JF; Ducharme MP; Morin I; Engel C; Gulbranson S; Thudi NR; Murpani D; Rampal A; Monif T; Koundinya TS; Deo K; Monif T Int J Clin Pharmacol Ther; 2008 Jun; 46(6):319-26. PubMed ID: 18541129 [TBL] [Abstract][Full Text] [Related]
10. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Hartmann D; Hussain Y; Güzelhan C; Odink J Br J Clin Pharmacol; 1993 Sep; 36(3):266-70. PubMed ID: 9114915 [TBL] [Abstract][Full Text] [Related]
11. Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. O'Donovan D; Feinle-Bisset C; Wishart J; Horowitz M Br J Nutr; 2003 Nov; 90(5):849-52. PubMed ID: 14667178 [TBL] [Abstract][Full Text] [Related]
12. Influence of dietary composition on the inhibition of fat absorption by orlistat. Güzelhan C; Odink J; Niestijl Jansen-Zuidema JJ; Hartmann D J Int Med Res; 1994; 22(5):255-65. PubMed ID: 7867870 [TBL] [Abstract][Full Text] [Related]
13. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. Zhi J; Moore R; Kanitra L; Mulligan TE J Clin Pharmacol; 2003 Apr; 43(4):428-35. PubMed ID: 12723464 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Carrière F; Renou C; Ransac S; Lopez V; De Caro J; Ferrato F; De Caro A; Fleury A; Sanwald-Ducray P; Lengsfeld H; Beglinger C; Hadvary P; Verger R; Laugier R Am J Physiol Gastrointest Liver Physiol; 2001 Jul; 281(1):G16-28. PubMed ID: 11408251 [TBL] [Abstract][Full Text] [Related]
15. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. Melia AT; Zhi J; Koss-Twardy SG; Min BH; Smith BL; Freundlich NL; Arora S; Passe SM J Clin Pharmacol; 1995 Aug; 35(8):840-3. PubMed ID: 8522642 [TBL] [Abstract][Full Text] [Related]
16. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380 [TBL] [Abstract][Full Text] [Related]
17. Orlistat: a review of its use in the management of obesity. Hvizdos KM; Markham A Drugs; 1999 Oct; 58(4):743-60. PubMed ID: 10551441 [TBL] [Abstract][Full Text] [Related]
18. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. Zhi J; Melia AT; Koss-Twardy SG; Min B; Guerciolini R; Freundlich NL; Milla G; Patel IH J Clin Pharmacol; 1995 May; 35(5):521-5. PubMed ID: 7657854 [TBL] [Abstract][Full Text] [Related]
19. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine. Sternby B; Hartmann D; Borgström B; Nilsson A Clin Nutr; 2002 Oct; 21(5):395-402. PubMed ID: 12381337 [TBL] [Abstract][Full Text] [Related]
20. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. Pace DG; Blotner S; Guerciolini R J Nutr; 2001 Jun; 131(6):1694-9. PubMed ID: 11385055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]